Cargando…
Immunological Outcome in Haploidentical-HSC Transplanted Patients Treated with IL-10-Anergized Donor T Cells
T-cell therapy after hematopoietic stem cell transplantation (HSCT) has been used alone or in combination with immunosuppression to cure hematologic malignancies and to prevent disease recurrence. Here, we describe the outcome of patients with high-risk/advanced stage hematologic malignancies, who r...
Autores principales: | Bacchetta, Rosa, Lucarelli, Barbarella, Sartirana, Claudia, Gregori, Silvia, Lupo Stanghellini, Maria T., Miqueu, Patrick, Tomiuk, Stefan, Hernandez-Fuentes, Maria, Gianolini, Monica E., Greco, Raffaella, Bernardi, Massimo, Zappone, Elisabetta, Rossini, Silvano, Janssen, Uwe, Ambrosi, Alessandro, Salomoni, Monica, Peccatori, Jacopo, Ciceri, Fabio, Roncarolo, Maria-Grazia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3907718/ https://www.ncbi.nlm.nih.gov/pubmed/24550909 http://dx.doi.org/10.3389/fimmu.2014.00016 |
Ejemplares similares
-
Innovative Platforms for Haploidentical Stem Cell Transplantation: The Role of Unmanipulated Donor Graft
por: Ciceri, Fabio, et al.
Publicado: (2011) -
Anergic Stupor
por: Dewar, Thomas W.
Publicado: (1884) -
Following-up allogeneic transplantation recipients during the COVID-19 pandemic
por: Lupo-Stanghellini, Maria Teresa, et al.
Publicado: (2020) -
T‐cell depleted HLA‐haploidentical HSCT in a child with neuromyelitis optica
por: Ceglie, Giulia, et al.
Publicado: (2019) -
The early expansion of anergic NKG2A(pos)/CD56(dim)/CD16(neg) natural killer represents a therapeutic target in haploidentical hematopoietic stem cell transplantation
por: Roberto, Alessandra, et al.
Publicado: (2018)